Key facts
- Resurrect Bio’s last known valuation is $6.2M (May 2023).
- It has raised $10.4M; the latest was Later Stage VC ($8.1M) in Feb 2026.
- Notable investors include Innovate UK, EIT Food, Future Planet Capital, StartLife, AgFunder — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Resurrect Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Resurrect Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Resurrect Bio
Manufacturer of plant biotechnology products designed for enhancing disease resistance in crops through immune system restoration. The company combines proprietary AI-driven trait discovery with high-throughput in-silico and in-planta workflows to identify and reconstitute immune receptor networks, enabling agricultural producers to accelerate trait development, reduce dependence on chemical inputs, improve crop resilience, and address a broad spectrum of pathogens across diverse crop species.
- Sector
- Materials and Resources
- HQ
- London, United Kingdom
- Founded
- 2021
- Employees
- 14
- Website
- resurrect.bio/
- Ownership
- Privately Held (backing)
Resurrect Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Resurrect Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Resurrect Bio in its N-PORT filings yet. We sweep new filings monthly.